Bio-Rad develops products and solutions for the life sciences research and clinical diagnostic markets and enjoys niche market leadership in diagnostic quality controls, antigens, and digital ...
Abstract: Diffusion models have achieved remarkable success in image generation, with applications broadening across various domains. Inpainting is one such application that can benefit significantly ...
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript February 12, 2026 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.51 EPS, expectations were $2.57.
Moby Strategic Performance Drivers and Operational Context. Management attributed the Q4 gross margin miss to execution- ...
Bio-Rad Laboratories Inc (BIO) reports a 3.9% sales increase in Q4 2025, driven by diagnostics growth, despite supply chain and market headwinds.
Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...
Bio-Rad Laboratories, Inc. ( BIO) Q4 2025 Earnings Call February 12, 2026 5:00 PM EST Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results